Clinical Research in Cardiology

, Volume 101, Issue 10, pp 829–836 | Cite as

Adverse effects of permanent atrial fibrillation on heart failure in patients with preserved left ventricular function and chronic right apical pacing for complete heart block

  • Brigitte Lampe
  • Christoph Hammerstingl
  • Jörg Otto Schwab
  • Fritz Mellert
  • Birgit Stoffel-Wagner
  • Andreas Grigull
  • Rolf Fimmers
  • Bernhard Maisch
  • Georg Nickenig
  • Thorsten Lewalter
  • Alexander Yang
Original Paper

Abstract

Background

The impact of atrial fibrillation (AF) on heart failure (HF) was evaluated in patients with preserved left ventricular (LV) function and long-term right ventricular (RV) pacing for complete heart block.

Methods

Clinical, echocardiographic, and laboratory parameters of HF were assessed in 35 patients with established AF who had undergone ablation of the atrioventricular node and pacemaker implantation (Group A) and 31 patients who received dual-chamber pacing for spontaneous complete heart block (Group B).

Results

During a follow-up period of 12.7 ± 7.5 years, New York Heart Association (NYHA) functional class increased from 1.3 ± 0.5 to 2.1 ± 0.6 (p < 0.0001) in Group A, and from 1.3 ± 0.4 to 1.6 ± 0.7 (p < 0.01) in Group B. Left ventricular ejection fraction (LVEF) decreased from 59.7 ± 5.1 to 53.0 ± 8.2 (p < 0.0001) in Group A, but remained stable (58.6 ± 4.2 vs. 56.9 ± 7.0 %, p = 0,21) in Group B. At the end of follow-up, markers of LV function were moderately depressed in Group A compared with those in Group B: NYHA class 2.1 ± 0.6 versus 1.6 ± 0.7, p = 0.001; LVEF 53.0 ± 8.2 versus 56.9 ± 7.0 %, p < 0.05; LV diastolic diameter 53.6 ± 5.8 mm versus 50.7 ± 4.9 mm, p < 0.05; N-terminal pro-brain natriuretic peptide (NT-proBNP) 1116.8 ± 883.9 versus 622.9 ± 1059.4 pg/ml, p < 0.05. Progression of paroxysmal AF to permanent AF during follow-up was common, while new onset of AF was rare. Permanent AF was an independent predictor of declining LVEF >10 %, increasing NYHA class ≥1, and NT-proBNP levels >1,000 pg/ml.

Conclusions

Permanent AF was associated with adverse effects on LV function and symptoms of HF in patients with long-term RV pacing for complete heart block, and appears to play an important role in the development of HF in this specific patient cohort.

Keywords

Atrial fibrillation Atrioventricular node Ablation Pacemaker Heart failure 

References

  1. 1.
    Scheinman MM, Morady F, Hess DS, Gonzalez R (1982) Catheter-induced ablation of the atrioventricular junction to control refractory supraventricular arrhythmia. JAMA 248:851–855PubMedCrossRefGoogle Scholar
  2. 2.
    Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 12:1360–1420PubMedCrossRefGoogle Scholar
  3. 3.
    Brignole M, Gianfranchi L, Menozzi C, Alboni P, Musso G, Bongiorni MG, Gasparini M, Raviele A, Lolli G, Paparella N, Acquarone S (1997) Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation: a randomized controlled study. Circulation 96:2617–2624PubMedCrossRefGoogle Scholar
  4. 4.
    Takahashi Y, Yoshito I, Takahashi A, Harada T, Mitsuhashi T, Shirota K, Kumagai K, Nuruki N, Shiraishi T, Nitta J, Ito H (2003) AV nodal ablation and pacemaker implantation improves hemodynamic function in atrial fibrillation. Pacing Clin Electrophysiol 26:1212–1217PubMedCrossRefGoogle Scholar
  5. 5.
    Weerasooriya R, Davis M, Powell A, Szili-Torok T, Shah C, Whalley D, Kanagaratnam L, Heddle W, Leitch J, Perks A, Ferguson L, Bulsara M (2003) The Australian intervention randomized control of rate in atrial fibrillation trial (AIRCRAFT). J Am Coll Cardiol 41:1697–1702PubMedCrossRefGoogle Scholar
  6. 6.
    Ozcan C, Jahangir A, Friedman PA, Patel PJ, Munger TM, Rea RF, Lloyd MA, Packer DL, Hodge DO, Gersh BJ, Hammill SC, Shen WK (2001) Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med 344:1043–1051PubMedCrossRefGoogle Scholar
  7. 7.
    Tan ES, Rienstra M, Wiesfeld AC, Schoonderwoerd BA, Hobbel HH, Van Gelder IC (2008) Long-term outcome of the atrioventricular node ablation and pacemaker implantation for symptomatic refractory atrial fibrillation. Europace 10:412–418PubMedCrossRefGoogle Scholar
  8. 8.
    Tops LF, Schalij MJ, Holman ER, van Erven L, van der Wall EE, Bax JJ (2006) Right ventricular pacing can induce ventricular dyssynchrony in patients with atrial fibrillation after atrioventricular node ablation. J Am Coll Cardiol 48:1642–1648PubMedCrossRefGoogle Scholar
  9. 9.
    Vernooy K, Dijkman B, Cheriex EC, Prinzen FW, Crijns HJ (2006) Ventricular remodeling during long-term right ventricular pacing following His bundle ablation. Am J Cardiol 97:1223–1227PubMedCrossRefGoogle Scholar
  10. 10.
    Thambo JB, Bordachar P, Garrigue S, Lafitte S, Sanders P, Reuter S, Girardot R, Crepin D, Reant P, Roudaut R, Jaïs P, Haïssaguerre M, Clementy J, Jimenez M (2004) Detrimental ventricular remodeling in patients with congenital complete heart block and chronic right ventricular apical pacing. Circulation 110:3766–3772PubMedCrossRefGoogle Scholar
  11. 11.
    Sweeney MO, Hellkamp AS, Ellenbogen KA, Greenspon AJ, Freedman RA, Lee KL, Lamas GA (2003) Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 107:2932–2937PubMedCrossRefGoogle Scholar
  12. 12.
    Willems R, Wyse DG, Gillis AM (2003) Total atrioventricular nodal ablation increases atrial fibrillation burden in patients with paroxysmal atrial fibrillation despite continuation of antiarrhythmic drug therapy. J Cardiovasc Electrophysiol 14:1296–1301PubMedCrossRefGoogle Scholar
  13. 13.
    Middlekauff HR, Stevenson WG, Stevenson LW (1991) Prognostic significance of atrial fibrillation in advanced heart failure. Circulation 84:40–48PubMedCrossRefGoogle Scholar
  14. 14.
    Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D’Agostino RB, Murabito JM, Kannel WB, Benjamin EJ (2003) Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 107:2920–2925PubMedCrossRefGoogle Scholar
  15. 15.
    ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117Google Scholar
  16. 16.
    Buck T, Breithardt OA, Faber L, Fehske W, Flachskampf FA, Franke A, Hagendorff A, Hoffmann R, Kruck I, Kücherer H, Menzel T, Pethig K, Tiemann K, Voigt JU, Weidemann F, Nixdorff U (2009) Manual zur Indikation und Durchführung der Echokardiographie. Clin Res Cardiol 4(Suppl 1):3–51Google Scholar
  17. 17.
    Olgin JE, Scheinman MM (1993) Comparison of high energy direct current and radiofrequency catheter ablation of the atrioventricular junction. J Am Coll Cardiol 21:557–564PubMedCrossRefGoogle Scholar
  18. 18.
    Geelen P, Brugada J, Andries E, Brugada P (1997) Ventricular fibrillation and sudden cardiac death after radiofrequency catheter ablation of the atrioventricular junction. Pacing Clin Electrophysiol 20:343–348PubMedCrossRefGoogle Scholar
  19. 19.
    Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, Puu M, Yusuf S, Pfeffer MA (2006) Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 47:1997–2004Google Scholar
  20. 20.
    Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L (2009) A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 11:676–683Google Scholar
  21. 21.
    Ellinor PT, Low AF, Patton KK, Shea MA, Macrae CA (2005) Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation. J Am Coll Cardiol 45:82–86PubMedCrossRefGoogle Scholar
  22. 22.
    Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, Kronmal RA (2009) N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the cardiovascular health study. Circulation 120:1768–1774PubMedCrossRefGoogle Scholar
  23. 23.
    Silvet H, Young-Xu Y, Walleigh D, Ravid S (2003) Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am J Cardiol 92:1124–1127PubMedCrossRefGoogle Scholar
  24. 24.
    Buob A, Jung J, Siaplaouras S, Neuberger HR, Mewis C (2006) Discordant regulation of CRP and NT-proBNP plasma levels after electrical cardioversion of persistent atrial fibrillation. Pacing Clin Electrophysiol 29:559–563PubMedCrossRefGoogle Scholar
  25. 25.
    Inoue S, Murakami Y, Sano K, Katoh H, Shimada T (2000) Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 6:92–96PubMedCrossRefGoogle Scholar
  26. 26.
    Tuinenburg AE, Brundel BJ, Van Gelder IC, Henning RH, Van Den Berg MP, Driessen C, Grandjean JG, Van Gilst WH, Crijns HJ (1999) Gene expression of the natriuretic peptide system in atrial tissue of patients with paroxysmal and persistent atrial fibrillation. J Cardiovasc Electrophysiol 10:827–835PubMedCrossRefGoogle Scholar
  27. 27.
    Hsu LF, Jaïs P, Sanders P, Garrigue S, Hocini M, Sacher F, Takahashi Y, Rotter M, Pasquié JL, Scavée C, Bordachar P, Clémenty J, Haïssaguerre M (2004) Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 351:2373–2383PubMedCrossRefGoogle Scholar
  28. 28.
    Hagens VE, Crijns HJ, Van Veldhuisen DJ, Van Den Berg MP, Rienstra M, Ranchor AV, Bosker HA, Kamp O, Tijssen JG, Veeger NJ, Van Gelder IC (2005) Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J 149:1106–1111PubMedCrossRefGoogle Scholar
  29. 29.
    Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O’Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL (2008) Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358:2667–2777PubMedCrossRefGoogle Scholar
  30. 30.
    Doshi RN, Daoud EG, Fellows C, Turk K, Duran A, Hamdan MH, Pires LA (2005) Left ventricular-based cardiac stimulation post AV nodal ablation evaluation. J Cardiovasc Electrophysiol 16:1160–1165PubMedCrossRefGoogle Scholar
  31. 31.
    Funck RC, Blanc JJ, Mueller HH, Schade-Brittinger C, Bailleul C, Maisch B (2006) Biventricular stimulation to prevent cardiac desynchronization: rationale, design, and endpoints of the ‘Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization (BioPace) study. Europace 8:629–635PubMedCrossRefGoogle Scholar
  32. 32.
    De Teresa E, Gómez-Doblas JJ, Lamas G, Alzueta J, Fernández-Lozano I, Cobo E, Navarro X, Navarro-López F, Stockburger M (2007) Preventing ventricular dysfunction in pacemaker patients without advanced heart failure: rationale and design of the PREVENT-HF study. Europace 9:442–446PubMedCrossRefGoogle Scholar
  33. 33.
    Edelmann F, Stahrenberg R, Gelbrich G, Durstewitz K, Angermann CE, Düngen HD, Scheffold T, Zugck C, Maisch B, Regitz-Zagrosek V, Hasenfuss G, Pieske BM, Wachter R (2011) Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clin Res Cardiol 100:755–764PubMedCrossRefGoogle Scholar
  34. 34.
    Reil JC, Custodis F, Swedberg K, Komajda M, Borer JS, Ford I, Tavazzi L, Laufs U, Böhm M (2011) Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol 100:11–19PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Brigitte Lampe
    • 1
  • Christoph Hammerstingl
    • 1
  • Jörg Otto Schwab
    • 1
  • Fritz Mellert
    • 2
  • Birgit Stoffel-Wagner
    • 3
  • Andreas Grigull
    • 3
  • Rolf Fimmers
    • 4
  • Bernhard Maisch
    • 5
  • Georg Nickenig
    • 1
  • Thorsten Lewalter
    • 1
  • Alexander Yang
    • 1
    • 6
  1. 1.Department of CardiologyUniversity of BonnBonnGermany
  2. 2.Department of Cardiac SurgeryUniversity of BonnBonnGermany
  3. 3.Department of Clinical Chemistry and Clinical PharmacologyUniversity of BonnBonnGermany
  4. 4.Department of Statistics and Medical BiometryUniversity of BonnBonnGermany
  5. 5.Department of CardiologyPhilipps UniversitätMarburgGermany
  6. 6.Medizinische Klinik und Poliklinik IIUniversitätsklinikum BonnBonnGermany

Personalised recommendations